For advanced NSCLC, the discovery of oncogenic driver mutations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase gene rearrangements, has led to novel strategies of classifying NSCLC and the option of utilizing appropriate tyrosine kinase inhibitors (TKIs) for anticancer therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.